BCRX

BioCryst Pharmaceuticals, Inc. is a cutting-edge biotechnology company headquartered in Durham, North Carolina, dedicated to pioneering oral and small molecule therapeutics for rare diseases. The company’s robust pipeline features innovative treatments aimed at addressing significant unmet medical needs, with a particular emphasis on hereditary angioedema and viral infections. BioCryst is recognized for its scientific rigor and nimble approach to drug development, making it an appealing investment for institutional investors looking for growth opportunities in the burgeoning rare disease therapeutic landscape.